Venus Medtech (Hangzhou) Inc. (HKG:2500)
Hong Kong · Delayed Price · Currency is HKD 2.880
-0.070 (-2.37%)
Feb 11, 2026, 4:08 PM HKT
Venus Medtech (Hangzhou) Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 427.25 | 470.83 | 491.37 | 406.46 | 415.86 | 276.05 | |
Revenue Growth (YoY) | -8.41% | -4.18% | 20.89% | -2.26% | 50.65% | 18.34% |
Cost of Revenue | 103.28 | 103.09 | 102.17 | 92.46 | 91.52 | 48.77 |
Gross Profit | 323.97 | 367.75 | 389.21 | 314 | 324.34 | 227.28 |
Selling, General & Admin | 338.77 | 391.09 | 454.26 | 436.76 | 344.65 | 238.64 |
Research & Development | 281.28 | 341.19 | 524.92 | 527.45 | 258.34 | 167.25 |
Other Operating Expenses | - | - | - | 21.97 | 3.19 | -0.05 |
Operating Expenses | 620.81 | 733.37 | 977.75 | 986.18 | 606.17 | 405.84 |
Operating Income | -296.84 | -365.62 | -588.55 | -672.19 | -281.83 | -178.56 |
Interest Expense | -14.01 | -16.65 | -62.72 | -44.62 | -1.91 | -2.16 |
Interest & Investment Income | 10.35 | 10.35 | 34.46 | 34.65 | 49.48 | 34.67 |
Earnings From Equity Investments | -5.78 | -4.15 | -12.38 | -13.94 | -11.71 | 0.57 |
Currency Exchange Gain (Loss) | -3.62 | 0.88 | 2.26 | 81.73 | 10.01 | 44.13 |
Other Non Operating Income (Expenses) | -212.36 | -222.08 | -65.7 | -104.45 | -145.84 | -93.88 |
EBT Excluding Unusual Items | -522.26 | -597.28 | -692.63 | -718.82 | -381.79 | -195.23 |
Merger & Restructuring Charges | - | - | - | -15.8 | - | - |
Impairment of Goodwill | - | - | -231.26 | -304.3 | -189.96 | - |
Gain (Loss) on Sale of Investments | -81.41 | -81.41 | 45.48 | -5.69 | 1.33 | 1.31 |
Asset Writedown | -62.03 | -62.03 | -17.52 | -111.74 | -46.19 | - |
Other Unusual Items | - | - | 160.59 | - | 239.05 | 8.07 |
Pretax Income | -665.7 | -740.71 | -735.34 | -1,156 | -377.56 | -185.84 |
Income Tax Expense | -22.38 | -23.34 | -6.28 | -34.3 | -6.16 | -2.98 |
Earnings From Continuing Operations | -643.32 | -717.37 | -729.06 | -1,122 | -371.39 | -182.87 |
Minority Interest in Earnings | 0.73 | 3.07 | 25.3 | 64.34 | -2.24 | 0.88 |
Net Income | -642.59 | -714.31 | -703.75 | -1,058 | -373.64 | -181.99 |
Net Income to Common | -642.59 | -714.31 | -703.75 | -1,058 | -373.64 | -181.99 |
Shares Outstanding (Basic) | 438 | 438 | 438 | 438 | 439 | 409 |
Shares Outstanding (Diluted) | 438 | 438 | 438 | 438 | 439 | 409 |
Shares Change (YoY) | - | - | - | -0.15% | 7.16% | 31.58% |
EPS (Basic) | -1.47 | -1.63 | -1.61 | -2.42 | -0.85 | -0.44 |
EPS (Diluted) | -1.47 | -1.63 | -1.61 | -2.42 | -0.85 | -0.44 |
Free Cash Flow | -170.65 | -10.18 | -870.66 | -899.44 | -538.99 | -286.79 |
Free Cash Flow Per Share | -0.39 | -0.02 | -1.99 | -2.05 | -1.23 | -0.70 |
Gross Margin | 75.83% | 78.11% | 79.21% | 77.25% | 77.99% | 82.33% |
Operating Margin | -69.48% | -77.65% | -119.78% | -165.38% | -67.77% | -64.68% |
Profit Margin | -150.40% | -151.71% | -143.22% | -260.22% | -89.85% | -65.93% |
Free Cash Flow Margin | -39.94% | -2.16% | -177.19% | -221.28% | -129.61% | -103.89% |
EBITDA | -277.34 | -335.73 | -547.66 | -591.19 | -247.4 | -152.83 |
EBITDA Margin | -64.91% | -71.30% | -111.46% | -145.45% | -59.49% | -55.36% |
D&A For EBITDA | 19.5 | 29.89 | 40.88 | 80.99 | 34.43 | 25.73 |
EBIT | -296.84 | -365.62 | -588.55 | -672.19 | -281.83 | -178.56 |
EBIT Margin | -69.48% | -77.65% | -119.78% | -165.38% | -67.77% | -64.68% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.